Bouchey Financial Group Ltd Boosts Stake in AbbVie Inc. $ABBV

Bouchey Financial Group Ltd increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 36.7% during the second quarter, HoldingsChannel reports. The fund owned 5,375 shares of the company’s stock after buying an additional 1,442 shares during the period. Bouchey Financial Group Ltd’s holdings in AbbVie were worth $998,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ABBV. Nuveen LLC purchased a new position in shares of AbbVie in the 1st quarter valued at about $1,819,154,000. Assenagon Asset Management S.A. grew its position in AbbVie by 550.9% during the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock worth $804,116,000 after buying an additional 3,666,521 shares during the period. Goldman Sachs Group Inc. increased its holdings in AbbVie by 31.6% in the first quarter. Goldman Sachs Group Inc. now owns 14,646,908 shares of the company’s stock valued at $3,068,820,000 after buying an additional 3,519,187 shares in the last quarter. Kingstone Capital Partners Texas LLC purchased a new position in AbbVie in the second quarter valued at about $581,817,000. Finally, Invesco Ltd. lifted its position in shares of AbbVie by 17.5% during the 1st quarter. Invesco Ltd. now owns 8,367,049 shares of the company’s stock valued at $1,753,064,000 after acquiring an additional 1,246,863 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

NYSE:ABBV opened at $225.06 on Wednesday. AbbVie Inc. has a 12-month low of $163.81 and a 12-month high of $244.81. The firm has a market cap of $397.76 billion, a price-to-earnings ratio of 107.17, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The company’s 50-day moving average is $223.67 and its two-hundred day moving average is $203.22. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.1%. AbbVie’s payout ratio is presently 524.24%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on ABBV shares. HSBC set a $225.00 price target on AbbVie in a report on Thursday, October 2nd. Daiwa America raised AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 7th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. Morgan Stanley lifted their price target on AbbVie from $250.00 to $255.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Finally, Guggenheim increased their price objective on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $236.57.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.